Skip to main content
GutCited

Saccharomyces boulardii के लिए Traveler's Diarrhea

B

RCTs show 25-40% reduction in traveler's diarrhea when started 5 days before travel. Effects vary by destination.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dtravelers\u002Ddiarrhea'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

निष्कर्ष

RCTs show 25-40% reduction in traveler's diarrhea when started 5 days before travel. Effects vary by destination.

Key Study Findings

Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None बनाम: placebo Outcome: improvement in key IBS symptoms प्रभाव: None None

जनसंख्या: patients with IBS from 32 RCTs evaluating 10 probiotic strains

Randomized Controlled Trial n=47 8 weeks Double-blind
Effects of a polyphenol-rich extract blend, probiotics, and hydrolyzed fiber on quality of life and …
Dose: None बनाम: Placebo (Group I) and partial formulation (Group II) Outcome: IBS quality of life (QoL questionnaire) प्रभाव: Dysphoria: median diff -5 (Group III) vs -1 (contr 0.0021 (dysphoria Group III)

जनसंख्या: Patients with IBS

Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None बनाम: None Outcome: Clinical guideline recommendations for pediatric GI प्रभाव: None None

जनसंख्या: Pediatric patients with GI disorders

Observational Study n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None बनाम: None Outcome: Probiotic prescribing habits of Italian PCPs प्रभाव: L. rhamnosus GG used by 91.8% None

जनसंख्या: Italian primary care pediatricians

Other n=70 16 weeks Open-label
Synbiotic Supplementation for Chronic Constipation in Patients Under Peritoneal Dialysis: An Italian Multicenter Prospective Study.
Dose: None बनाम: None (single-arm study) Outcome: Constipation scoring system change प्रभाव: -5.3 (95% CI -5.9/-4.7) 0.001

जनसंख्या: Peritoneal dialysis patients with chronic constipation

Review
An update on probiotics in paediatrics.
Dose: None बनाम: None Outcome: GI disorder outcomes in paediatrics प्रभाव: None None

जनसंख्या: Paediatric patients with GI disorders

Key Statistics

4

अध्ययन

3200

प्रतिभागी

Positive

B

ग्रेड

Referenced Papers

Journal of gastroenterology … 2025 10 उद्धरण
Current opinion in … 2025
Advances in experimental … 2024 2 उद्धरण
Therapeutic advances in … 2023 97 उद्धरण
The Journal of … 2023 1 उद्धरण
Archivos argentinos de … 2022 23 उद्धरण
Physiology & behavior 2021 35 उद्धरण
Advances in experimental … 2019 17 उद्धरण
World journal of … 2018 52 उद्धरण
The American journal … 2018 46 उद्धरण
Pediatric gastroenterology, hepatology … 2017 42 उद्धरण
Journal of pediatric … 2016 233 उद्धरण
Clinical and experimental … 2016 82 उद्धरण
Digestive diseases (Basel, … 2016 37 उद्धरण
The Cochrane database … 2015 233 उद्धरण
Journal of clinical … 2015 35 उद्धरण
Frontiers in immunology 2013 263 उद्धरण
Medycyna wieku rozwojowego 2012 1 उद्धरण
Journal of clinical … 2011 432 उद्धरण
World journal of … 2010 512 उद्धरण
Journal for specialists … 2010 22 उद्धरण
American journal of … 2010
European journal of … 2009 91 उद्धरण
Current opinion in … 2009 82 उद्धरण
Advances in biochemical … 2008 535 उद्धरण
American family physician 2008
The Journal of … 2007 265 उद्धरण
Nutrition (Burbank, Los … 2007 39 उद्धरण
The American journal … 2001 648 उद्धरण
International journal of … 2000 181 उद्धरण
Clinical infectious diseases … 1998 346 उद्धरण

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

सामान्य रूप से उपयोग की जाने वाली खुराकें

general:
250-500 mg/day (equivalent to 5-10 billion CFU)
aadprevention:
500 mg/day (start with antibiotic, continue 7 days after)
cdiffprevention:
500 mg twice daily as adjunct to standard therapy
travelersdiarrhea:
250-500 mg/day starting 5 days before travel

अधिकतम सीमा: Well-tolerated up to 1,000 mg/day in clinical trials

अनुसंधान में अध्ययन की गई खुराकें

खुराक अवधि प्रभाव N
None -- Positive --
None 8 weeks Positive 47
None -- Positive --
None -- Mixed 279
None 16 weeks Positive 70
None -- Positive --
None -- Positive --
None -- Mixed --

सेवन का सर्वोत्तम समय: Can be taken with or without food; space 2 hours from antifungals

Safety & Side Effects

रिपोर्ट किए गए दुष्प्रभाव

  • Mild gas and bloating
  • Rare: fungemia in critically ill patients with central venous catheters
  • Thirst (yeast may increase water requirements)
  • Very rare: potential environmental contamination risk in ICU settings

ज्ञात अंतःक्रियाएँ

  • Antifungal medications (may kill S. boulardii, reducing effectiveness)
  • Monoamine oxidase inhibitors (S. boulardii contains tyramine)
  • Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)

सहनीय अधिकतम सेवन: Well-tolerated up to 1,000 mg/day in clinical trials

कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।

Frequently Asked Questions

Does Saccharomyces boulardii help with Traveler's Diarrhea?
Based on 4 studies with 3,200 participants, there is moderate evidence from clinical studies that Saccharomyces boulardii may support Traveler's Diarrhea management. Our evidence grade is B (Good Evidence).
How much Saccharomyces boulardii should I take for Traveler's Diarrhea?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and Traveler's Diarrhea?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 3,200 total participants. The overall direction of effect is positive.

Related Evidence

इसके लिए अन्य सामग्री Traveler's Diarrhea

Saccharomyces boulardii अन्य स्वास्थ्य स्थितियों के लिए

FDA अस्वीकरण: इन कथनों का Food and Drug Administration द्वारा मूल्यांकन नहीं किया गया है। इस वेबसाइट पर उत्पादों और जानकारी का उद्देश्य किसी बीमारी का निदान, उपचार, इलाज या रोकथाम नहीं है। प्रस्तुत साक्ष्य ग्रेड प्रकाशित पीयर-रिव्यूड अनुसंधान के हमारे विश्लेषण पर आधारित हैं और चिकित्सा सलाह नहीं हैं। कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।